


## DA 3003-2

<b>Cat. No.:</b>	HY-118798
<b>CAS No.:</b>	383907-47-9
<b>Molecular Formula:</b>	C <sub>15</sub> H <sub>16</sub> ClN <sub>3</sub> O <sub>3</sub>
<b>Molecular Weight:</b>	321.76
<b>Target:</b>	Phosphatase
<b>Pathway:</b>	Metabolic Enzyme/Protease
<b>Storage:</b>	4°C, sealed storage, away from moisture and light * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)



### SOLVENT & SOLUBILITY

<b>In Vitro</b>	DMSO : 150 mg/mL (466.19 mM; Need ultrasonic)																					
	<table border="1"> <thead> <tr> <th rowspan="2">Solvent</th> <th rowspan="2">Mass</th> <th colspan="3">Concentration</th> </tr> <tr> <th>1 mg</th> <th>5 mg</th> <th>10 mg</th> </tr> </thead> <tbody> <tr> <td rowspan="3">Preparing Stock Solutions</td> <td>1 mM</td> <td>3.1079 mL</td> <td>15.5395 mL</td> <td>31.0791 mL</td> </tr> <tr> <td>5 mM</td> <td>0.6216 mL</td> <td>3.1079 mL</td> <td>6.2158 mL</td> </tr> <tr> <td>10 mM</td> <td>0.3108 mL</td> <td>1.5540 mL</td> <td>3.1079 mL</td> </tr> </tbody> </table>	Solvent	Mass	Concentration			1 mg	5 mg	10 mg	Preparing Stock Solutions	1 mM	3.1079 mL	15.5395 mL	31.0791 mL	5 mM	0.6216 mL	3.1079 mL	6.2158 mL	10 mM	0.3108 mL	1.5540 mL	3.1079 mL
Solvent	Mass			Concentration																		
		1 mg	5 mg	10 mg																		
Preparing Stock Solutions	1 mM	3.1079 mL	15.5395 mL	31.0791 mL																		
	5 mM	0.6216 mL	3.1079 mL	6.2158 mL																		
	10 mM	0.3108 mL	1.5540 mL	3.1079 mL																		
	Please refer to the solubility information to select the appropriate solvent.																					
<b>In Vivo</b>	1. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 3.75 mg/mL (11.65 mM); Clear solution																					

### BIOLOGICAL ACTIVITY

<b>Description</b>	DA 3003-2 is a potent and selectively Cdc25 inhibitor. DA 3003-2 shows antiproliferative activity. DA 3003-2 induces cell cycle arrest at the G2/M phase and increases the expression of P-tyr <sup>15</sup> Cdc2. DA 3003-2 has the potential for the research of prostate cancer <sup>[1]</sup> .				
<b>In Vitro</b>	<p>DA 3003-2 (0.3-30 μM; 48 h) shows antiproliferative activity with an IC<sub>50</sub> value of 5 μM in PC-3 cells<sup>[1]</sup>.</p> <p>DA 3003-2 (5, 10 μM; 24, 1 h) induces cell cycle arrest at G2/M phase and increases the expression of P-tyr<sup>15</sup> Cdc2 in PC-3 cells<sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Cytotoxicity Assay<sup>[1]</sup></p> <table border="1"> <tr> <td>Cell Line:</td> <td>PC-3 cells</td> </tr> <tr> <td>Concentration:</td> <td>0.3-30 μM</td> </tr> </table>	Cell Line:	PC-3 cells	Concentration:	0.3-30 μM
Cell Line:	PC-3 cells				
Concentration:	0.3-30 μM				

Incubation Time:	48 h
Result:	Showed antiproliferative efficacy in a dose-dependent manner with an IC <sub>50</sub> value of 5 μM.

#### Cell Cycle Analysis<sup>[1]</sup>

Cell Line:	PC-3 cells
Concentration:	5, 10 μM
Incubation Time:	24 h
Result:	Induced cell cycle arrest at G2/M phase.

#### Western Blot Analysis<sup>[1]</sup>

Cell Line:	PC-3 cells
Concentration:	5, 10 μM
Incubation Time:	1 h
Result:	Increased the expression of P-tyr <sup>15</sup> Cdc2.

## REFERENCES

[1]. Nemoto K. G2/M accumulation in prostate cancer cell line PC-3 is induced by Cdc25 inhibitor 7-chloro-6-(2-morpholin-4-ylethylamino) quinoline-5, 8-dione (DA 3003-2). Exp Ther Med. 2010 Jul;1(4):647-650.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA